SAN DIEGO--(BUSINESS WIRE)--Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders, including obesity, is scheduled to present an overview of its novel understanding of the current obesity epidemic. This understanding is the basis of new strategies that we believe have the potential to change the way obesity is treated and address co-morbidities associated with obesity such as diabetes, heart disease, and depression. Gary Tollefson, M.D., Ph.D., Orexigen President and CEO, will detail the Company’s novel approaches during a panel discussion entitled “Confronting Obesity” at the 2008 BIO International Convention. The panel will take place on June 18 at 4:00 P.M. Pacific Time in room 30A of the San Diego Convention Center.
